Articles from BostonGene Corporation

BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced another major independent validation of its AI and machine learning (ML) capabilities in a landmark blinded, multi-vendor HER2 benchmarking study. The results, published in the Modern Pathology article, “Agreement Across 10 Artificial Intelligence Models in Assessing Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Whole-Slide Images” were conducted in collaboration with Friends of Cancer Research and supported by leading global pharmaceutical companies and patient advocacy stakeholders.

BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Ottimo Pharma Limited (“Ottimo”), an innovative, clinical-stage biotech company developing one-of-a-kind PD-1/VEGFR2 dual paratopic antibodies to extend the lives of patients living with cancer. The partnership will utilize BostonGene’s advanced artificial intelligence (AI) platform to apply multiomic analytics and expedite the clinical development of Ottimo’s novel therapeutic candidate, OTP-01. OTP-01 is a first-in-class, bifunctional, dual paratopic antibody therapeutic that maintains a conventional IgG architecture while being engineered to simultaneously inhibit two critical signaling pathways, PD-1 and VEGFR2, with the goal of enhancing anti-tumor immunity and overcoming both primary and acquired resistance that limit the effectiveness of current immuno-oncology approaches.

BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, to advance oncology drug development using BostonGene’s multimodal AI platform.

BostonGene, developer of the leading AI foundation model for cancer and the immune system, today announced that it will showcase its latest advances at the Association for Molecular Pathology (AMP) 2025 Annual Meeting & Expo, the premier global gathering of molecular professionals driving innovation in diagnostics, drug development and patient care. The event is scheduled for November 11–15, 2025, at the Thomas M. Menino Convention and Exhibition Center in Boston, Massachusetts.

BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced the publication of a collaborative study*, “AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma,” in Cell Reports Medicine. The study introduced the largest harmonized transcriptomic and clinical dataset in kidney cancer and presents a model of how advanced multimodal AI solutions can identify previously unknown determinants of response to combinations of immunotherapy and VEGF inhibitors in solid tumors.

BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced that six abstracts have been accepted at the 2025 ASCO Annual Meeting (ASCO), scheduled to take place May 31 – June 3, 2025, at McCormick Place Convention Center in Chicago, IL. BostonGene will also exhibit at booth #15147.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced that it has garnered the “Cancer Immunology Solution of the Year” award in the fourth annual BioTech Breakthrough Awards program. The awards, conducted by BioTech Breakthrough—a market intelligence organization recognizing standout life sciences and biotechnology companies—highlight top global innovations.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced its participation in the Friends of Cancer Research (Friends) meeting, Advancing the Future of Diagnostics and Regulatory Innovations. The event, which aims to drive innovation in diagnostics and regulatory policy, will be held on February 4 at the Ritz Carlton in Washington, DC.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced its participation in The Festival of Genomics & Biodata 2025, held January 29 – 30, at ExCel in London, UK. Celebrating its 10th anniversary, the Festival is the UK’s largest life sciences event, offering an expanded lineup of topics including biodata, diagnostics, cancer research, AI and multiomics.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced that it will participate in the 36th edition of the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024), taking place October 23-25, 2024, at the International Barcelona Convention Center in Barcelona, Spain. The event will bring together academics, scientists and industry leaders from around the world to discuss innovations in drug development, target selection and translational cancer research. ENA 2024 offers a valuable platform for in-depth scientific discussions on preclinical and phase I studies and for sharing insights on advancements in molecular targets and cancer therapeutics, with a focus on the implications of molecular biology discoveries.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced its participation in the 14th Annual Association for Value-Based Cancer Care (AVBCC) Summit and Educational Program. The summit, scheduled for October 16 - 18 in New York City, will bring together oncology professionals, payers, and industry leaders to explore the implementation of value-based models aimed at enhancing the quality and cost effectiveness of cancer care. This year’s Summit will focus on multiomic data utilization, biomarker-driven treatment strategies, and the integration of payer metrics to advance value-based practices in oncology.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced today that it has been named a Category Award Winner in the 2024 Clinical Trials Arena Excellence Awards, earning four awards across three categories: Innovation, Product Launches and Marketing. These awards underscore BostonGene’s continued commitment to revolutionizing cancer care and driving advancements in precision medicine.

BostonGene a leading provider of artificial intelligence (AI)-driven molecular and immune profiling solutions, announced today its participation in the European Federation of Laboratory Medicine (EFLM) Strategic Conference 2024, to be held in Padua, Italy, from September 23 to 24. The event, titled "A Vision to the Future: Value-Based Laboratory Medicine," will focus on shaping the future of laboratory medicine through innovative value-based approaches and integrated diagnostics.

BostonGene, a leading provider of AI-based molecular and immune profiling solutions, and researchers from multiple cancer centers including, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Weill Cornell Medicine and Washington University School of Medicine in St. Louis and others, today announced the online publication of the manuscript “Deep Clinical Responses and Limited Inflammatory Toxicity in Patients with Relapsed/Refractory T-cell Lymphomas Receiving Duvelisib and Romidepsin”* in Nature Medicine. The study highlights significant clinical responses and reduced inflammatory toxicity in patients with relapsed and refractory T-cell lymphomas treated with a combination of duvelisib and romidepsin.

BostonGene a leading provider of artificial intelligence (AI)-driven molecular and immune profiling solutions, announced today that it will present three abstracts at ESMO Congress 2024. This globally recognized oncology event brings together clinicians, researchers, patient advocates and healthcare professionals to share and discuss the latest advancements in translational cancer research. The Congress aims to highlight potentially practice-changing data and foster multidisciplinary discussions to enhance treatment options for cancer patients.

BostonGene, a leading provider of artificial intelligence (AI)-driven molecular and immune profiling solutions, has received one Gold Stevie for its AI-based digital pathology platform and two Silver Stevies for its Tumor PortraitTM test and immune system profiling platform in the Stevie Awards for Technology Excellence, “the Olympics for technology.”

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced they will collaborate with the Icahn School of Medicine at Mount Sinai on a precision medicine clinical study in multiple myeloma (MM). The study aims to evaluate and improve cancer sequencing for the characterization of tumor molecular vulnerabilities and the identification of novel therapeutics, paving the way for developing targeted therapies and personalized treatment approaches for MM patients.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced its participation in the 14th World Clinical Biomarkers & CDx Summit 2024, taking place September 3 - 6 in Boston, Massachusetts. The event will bring together drug developers, diagnostics providers, and payers to advance biomarker-driven clinical trials, focusing on early biomarker discovery, clinical strategy optimization and the commercialization of precision therapies. BostonGene will also exhibit at booth #19.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the presentation of its poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting has received the GRASP Advocate Choice Award. The poster details the results of a study that uncovered the intricate heterogeneity of the tumor microenvironment (TME) in invasive lobular carcinoma (ILC) of the breast, through bulk RNA-seq and spatial biology analyses, highlighting the importance of TME profiling in developing personalized treatments for ILC patients.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the publication, “Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer” in Cancer Cell, the premier scientific journal to publish articles with significant advances in cancer research and oncology. This study describes the development of a platform for patient immune system profiling, establishing a novel classification and scoring system that correlates systemic immunity with patient responses to various cancer treatments, highlighting a new discovery for drug development and clinical care. This groundbreaking innovative solution is based on a blood test coupled with powerful proprietary software and bioanalytics from BostonGene.

BostonGene, a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory. ComboMATCH is a follow-up to the largest precision medicine clinical trial, the National Cancer Institute (NCI)-MATCH trial. ComboMATCH aims to overcome drug resistance to single-drug therapies by developing targeted drug combinations. NCI is a part of the National Institutes of Health.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced it will participate in the United States and Canadian Academy of Pathology (USCAP) 113th Annual Meeting, the largest gathering of pathologists in the world. The event will be held from March 23 - 28, 2024, at the Baltimore Convention Center in Baltimore, Maryland. BostonGene will exhibit in booth #106.

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies and BostonGene Corporation (BostonGene), a leading company in AI-based molecular and immune profiling, today announced the expansion of their collaboration for the randomized Phase I/II trial of TG4050, an individualized therapeutic vaccine for patients with head and neck cancers.

BostonGene, a leading provider of AI-based molecular and immune profiling solutions, today announced the online publication of the manuscript “Clinical trial links oncolytic immunoactivation to survival in glioblastoma,” in Nature, an international journal publishing peer-reviewed research in all fields of science and technology prioritizing originality, significance, interdisciplinary relevance, timeliness, accessibility, sophistication, and groundbreaking findings.

BostonGene, a leading provider of AI-based molecular and immune profiling solutions provider, today announces a collaboration with Prisma Health aimed at advancing the understanding of rare tumors by characterizing the tumor microenvironment (TME), mutational landscape and host immune profiles of patients treated with immune checkpoint inhibitors.

CB Insights named BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, to its fifth-annual Digital Health 50 showcasing the 50 most promising private digital health companies of 2023.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the Company will present four posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023 at the San Diego Convention Center in San Diego, CA. BostonGene will also exhibit at booth 639.

BostonGene today announced an agreement with Hokkaido University Hospital to drive the discovery, validation and implementation of a groundbreaking stratification protocol for HER2-positive breast cancer patients.

BostonGene today announced its ASCO poster detailing the results of a study characterizing the differences between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC), including distinct genomic alterations, gene expression, transcriptomic features, TMEs, and biomarkers, received a GRASP Advocate Choice Award.

BostonGene announced today that it will participate in and present at the 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference on June 22 - 23 in Boston, MA. The event brings together academicians, researchers and scientists from research institutes, pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest advancements in the development of ADCs, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy. BostonGene will also exhibit at the conference.

BostonGene announced today that as part of its ongoing commitment to improving the diagnosis and personalized treatment recommendations for cancer patients, it will participate in and present at PEGS Boston Summit on May 15 – 19, 2023, at the Hynes Convention Center. The event is the leading biologics event covering all aspects of biologic drug development with in-depth presentations on protein and antibody engineering, immunotherapy, oncology, expression, analytics, immunogenicity, and more. BostonGene will also exhibit at booth #228.

BostonGene Corporation has announced a major research collaboration with Australia’s Mater Research to discover novel diagnostic biomarkers of follicular lymphoma and ultimately improve treatment for patients in the advanced stages of the disease.

BostonGene announced today that it will participate and present at the hubXchange’s East Coast Genomics in Precision Oncology 2023, taking place April 5 in Boston, Massachusetts. The event brings together executives from pharma and biotech to address and find solutions to the key issues that currently need to be addressed in genomics-led oncology precision medicine strategies.

BostonGene Corporation announced that three abstracts were selected for presentation at the United States and Canadian Academy of Pathology (USCAP) 112th Annual Meeting. The event will be held from March 11 - 16, 2023, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. BostonGene will exhibit in booth #457.

BostonGene Corporation announced today that it will participate in and present at Immuno-Oncology 360°, taking place February 7 – 10 in Brooklyn, New York. The event spans the ecosystem responsible for the development of Immuno-Oncology therapies and attracts leading pharma and biotech, academic key opinion leaders, life science investors, patient advocacy, technologists and services companies.

BostonGene Corporation today announced that two abstracts were selected for presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition. The event will be held from December 10 – 13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. BostonGene will exhibit in booth #2214.

BostonGene today announced that an abstract has been accepted for online publication for the Association for Molecular Pathology (AMP) 2022 Annual Meeting & Expo, which will be held November 3 - 5, 2022, at the Phoenix Convention Center in Phoenix, AZ. BostonGene will also exhibit at booth 943.

BostonGene Corporation today announced a Master Agreement with Massachusetts General Hospital Cancer Center, a member of the Mass General Brigham (MGB) healthcare system, to collaborate on multiple research projects. The alliance aims to support clinical research utilizing BostonGene’s CLIA-certified and CAP-accredited high complexity molecular laboratory and advanced computational algorithms to identify and validate novel precision medicine approaches.

BostonGene Corporation today announced a master agreement with New York’s Memorial Sloan Kettering Cancer Center (MSK) that includes multiple research initiatives. The collaboration will support pre-clinical and clinical research activities at MSK which utilize BostonGene’s CLIA-certified and CAP-accredited high complexity molecular laboratory and advanced computational algorithms that identify and validate novel precision medicine approaches.

BostonGene Corporation and Thomas Jefferson University announced the online publication of the manuscript, “Tadalafil enhances immune response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma” in the American Association for Cancer Research journal Clinical Cancer Research. The study revealed pretreatment head and neck squamous cell carcinoma specimens contain distinct HPV status-dependent signatures predictive of immunotherapy response, while post-treatment specimens treated with combination nivolumab and tadalafil exhibit tumor immune microenvironments enriched with B and natural killer cell-associated gene signatures.

BostonGene Corporation announced today expanded capabilities of the BostonGene Tumor Portrait TM Test that enable healthcare providers and insurance companies to determine eligibility and predict response for immunotherapy treatment and manage the total cost of care for cancer patients. A sophisticated analysis of the tumor and tumor microenvironment (TME), the BostonGene Tumor Portrait TM Test, reveals critical drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies.

BostonGene Corporation and WellDyne today announced a strategic partnership to improve therapeutic decision-making for cancer patients. With BostonGene Tumor Portrait™ Tests, WellDyne will increase efficiency and therapy selection for patients who are candidates for immunotherapy in melanoma, non-small cell lung cancer, gastric, bladder and kidney cancers.

BostonGene Corporation and NEC Corporation (NEC; TSE: 6701) today announced a strategic global partnership agreement that will enable the companies to offer BostonGene Tumor PortraitTM Tests in key international markets, including Japan as the first market outside of the U.S.

BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced that seven abstracts were selected for presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. The event will be held from December 11 – 14, 2021 at the Georgia World Congress Center. BostonGene will exhibit in booth #3765.

BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, announced today that BestStartup.us had named BostonGene a top Massachusetts startup in two categories, “Genetics” and “Bioinformatics."

BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients today announces a new publication in the peer-reviewed scientific journal Cancer Research, a journal of the American Association for Cancer Research. The study, performed in collaboration with Weill Cornell Medicine and titled “Oncogenic HSP90 facilitates metabolic alterations in aggressive B-cell lymphomas,” details the role of oncogenic heat shock protein 90 (HSP90) to support metabolic pathways in B-cell lymphoma cells and in patients with diffuse large B-cell lymphoma (DLBCL).

BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced two research collaborations with Massachusetts General Hospital (MGH), the largest hospital-based research program in the U.S. that delivers care grounded in leading-edge research, advanced treatment offerings and the latest clinical trials. The collaborations are designed to explore the role of tumor genetics and the tumor microenvironment of patients with follicular lymphoma (FL) and to understand their impact on disease transformation and response to treatment.

The University of Texas MD Anderson Cancer Center and BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced a strategic alliance to advance the development and clinical integration of multiplatform biomarker signatures.

BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced a publication in Blood Cancer Journal, a peer-reviewed journal that focuses on hematologic malignancies and related disorders. The manuscript “Lack of intrafollicular memory CD4+ T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma” underscores the role of intrafollicular CD4 expression to independently predict treatment outcomes of high-risk follicular lymphoma (FL) patients.

BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced the online publication of the manuscript, “Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer” in Clinical Cancer Research, a journal of the American Association for Cancer Research. The study, led by oncologists at Washington University School of Medicine in St. Louis – in collaboration with BostonGene – identified distinct molecular, cellular, and structural characteristics associated with MRI-visible clinically significant prostate cancer (csPCa).

BostonGene Corporation, a biomedical software company focused on defining optimal, precision medicine-based therapies for cancer patients, today announced that two abstracts have been accepted for online publication for the 2021 ASCO Annual Meeting.

BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced a publication in Cancer Cell, a premier peer-reviewed scientific journal that publishes high impact results in cancer research and oncology. The manuscript, “Conserved pan-cancer microenvironment subtypes predict response to immunotherapy”, describes a transcriptomic-based tumor classification platform that identifies distinct tumor microenvironment subtypes across a broad array of cancers, predicting prognosis and response to immune checkpoint blockade.

BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced a Master Clinical Research Collaboration Agreement with the Abramson Cancer Center (ACC) of the University of Pennsylvania to support multiple research projects at the cancer center.

BostonGene Corporation, a biomedical software company focused on defining optimal precision medicine-based therapies for cancer patients, today announced a research collaboration with the Medical College of Wisconsin (MCW) to analyze the role of the tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) in modulating the response to various therapies.